Australia: More Headaches For Reckitt Benckiser As GSK Wins Misleading Comparative Advertising Dispute

Last Updated: 16 May 2018
Article by Suzy Roessel

Justice Foster of the Federal Court has held that Reckitt Benckiser (Reckitt) lacked an adequate foundation in scientific knowledge to make certain representations to Australian consumers, including that "Nurofen is better than Panadol and paracetamol for the treatment of common headaches" and, as a consequence, found that Reckitt's Nurofen advertisements comparing those products were misleading, deceptive and false under the Australian Consumer Law, and that a declaration and final injunction should be ordered. This case provides a useful guide regarding the level of scientific support required to make a legally acceptable representation regarding the performance of a product in comparison to a competitor's product.


In 2015, we reported that the ACCC had successfully sued Reckitt for misleading and deceptive conduct regarding its Nurofen products targeting specific pain. This year, in an action commenced by GlaxoSmithKline Australia Pty Ltd and GlaxoSmithKline Consumer Healthcare Australia Pty Ltd (GSK), Reckitt has again fallen foul of the Australian Consumer Law regarding advertisements for its Nurofen products, this time with respect to an advertising campaign comparing the effect of Nurofen to the effect of Panadol for the relief of common headaches including tension-type headaches (TTH).

By a previous decision of Justice Foster, an interim injunction was ordered restraining Reckitt from engaging in further conduct of the advertising campaign until determination of whether there has been any contravention of the Australian Consumer Law and the nature and form of any declaratory and injunctive relief to be granted to the applicants. This interim injunction will remain in place until final orders are made. This decision considered and determined those matters.

The Representations

This case concerned an advertising and promotional campaign for Reckitt's Nurofen products, comprising print advertisements and a TV commercial. The advertisements presented a graph, which provides the results of a clinical trial (the Schachtel Study), which is said in the advertisements to demonstrate that Nurofen (with the active ingredient ibuprofen) provides faster and more effective pain relief than Panadol (with the active ingredient paracetamol). An example of the graph used in one of the advertisements is shown below.

Justice Foster found that , by the impugned advertisements, Reckitt:

(a) expressly represented that Nurofen, when taken in the recommended dose and as directed by the manufacturer, generally delivers faster and more effective relief from pain caused by common headaches including TTH than does Panadol or paracetamol.

(b) expressly represented that Nurofen is better than Panadol and paracetamol for the treatment of common headaches including TTH and performs in a superior manner to Panadol and paracetamol in delivering pain relief for such headaches.

(c) impliedly represented that, at the time when it conducted the campaign (August to December 2015), there was a current adequate foundation in scientific knowledge to support the representations set out in subparagraphs (a) and (b) above."

The outcome of the case therefore turned upon whether there was in fact an adequate foundation in scientific knowledge to support representations (a) and (b) above.

The Science

Reckitt and GSK referred to three clinical trials (the Schachtel Study, Study NL9701 and the NCT Study) and three meta-analyses (the Moore Study and two Cochrane reviews in 2015 and 2016 respectively) as the relevant scientific knowledge concerning comparisons between the effect of ibuprofen compared to the effect of paracetamol for the treatment of common headaches including TTH.

Both parties presented evidence from expert witnesses regarding interpretation of these studies and the conclusions to be drawn from them. Importantly, both experts agreed that Cochrane reviews were the "gold standard" for evaluating and comparing medication efficacy, because they attempt to include all studies whether published or unpublished in peer-reviewed journals.

Justice Foster found the following with respect to these studies:

  • The Schachtel Study supported the proposition that ibuprofen (Nurofen) provides faster and more effective relief than paracetamol (Panadol).
  • Both Study NL9701 and the NCT Study did not replicate the results of the Schachtel Study, nor did they invalidate or impugn the results of the Schachtel Study.
  • Both the Moore Study and the Cochrane reviews included in their review the Schachtel Study and Study NL9701, and Cochrane 2016 also included the NCT Study.
  • The Moore Study and the Cochrane reviews did not support the advertising campaign. These meta-analyses concluded that ibuprofen was not much different from any other treatment based on what was known.

The Outcome

Based on the findings outlined above, his Honour found that the balance of the scientific knowledge was that the Schachtel Study, taken alone, supports the proposition that "ibuprofen (Nurofen) provides faster and more effective relief than paracetamol (Panadol)", but Study NL9701 does not, nor does the NCT Study. Most importantly of all, however, none of the meta-analyses undertaken supported the claim.

On that basis, Justice Foster concluded that "it was too simplistic a view of the relevant body of scientific knowledge" for Reckitt to take support from the Schachtel Study on the basis that none of the other studies suggested or established that the results of the Schachtel Study were invalid or unsupportable.

His Honour concluded that "it is misleading or deceptive or likely to mislead or deceive consumers in Australia for Reckitt to claim that ibuprofen (Nurofen) provides faster and more effective relief from pain caused by common headaches including TTH than does paracetamol (Panadol) when the only study which supports such a clear cut claim is the Schachtel Study". His Honour therefore found that Reckitt had contravened s 18 of the Australian Consumer Law. In addition, His Honour found that, by making the representations, Reckitt had also contravened  ss29(1)(a) and (g) of the Australian Consumer Law by making false representations that the goods were of a particular standard and that the goods have certain performance characteristics.

Justice Foster stated that relief by way of declaration and injunction is appropriate, and has ordered the parties to file draft orders which they consider to reflect the reasons by 8 February 2018. The interim injunction will remain in place until the final orders have been made by his Honour.

Key Points for Comparative Advertising

  • A comparative promotion of a product necessarily indicates that the advertisement is not mere advertising puff, but involves representations of fact which are either true or false. Comparative advertising is therefore lawful provided that the factual assertions are not untrue or misleading half-truths.
  • Where claims are made of a scientific nature, proof that there is no scientific foundation or no adequate scientific foundation for those claims may be sufficient to establish that the claims are misleading.
  • It can be misleading to make a statement which implies that there is an adequate scientific foundation in scientific knowledge to justify it when, taken in its context, the scientific statement quoted does not provide a proper foundation
  • In the pharmaceutical context, Cochrane reviews are the "gold standard" for evaluating and comparing medication efficacy.
  • Reliance on the results of a single clinical trial will amount to a misrepresentation if those results are not supported in other relevant studies. This is particularly the case if a less favourable conclusion is drawn in a meta-analysis such as a Cochrane review.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on

Click to Login as an existing user or Register so you can print this article.

Some comments from our readers…
“The articles are extremely timely and highly applicable”
“I often find critical information not available elsewhere”
“As in-house counsel, Mondaq’s service is of great value”

Related Topics
Related Articles
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Registration (you must scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of

To Use you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.


The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.


Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions